| Title |
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
|
|---|---|
| Published in |
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, January 2013
|
| DOI | 10.2147/dmso.s23166 |
| Pubmed ID | |
| Authors |
Baptist Gallwitz |
| Abstract |
The first dipeptidyl-peptidase-IV (DPP-4) inhibitor for the treatment of type 2 diabetes became available in 2006. Since then, the number of DPP-4 inhibitors has increased and DPP-4 inhibitors have developed into an important drug class. DPP-4 inhibitors act by increasing endogenous GLP-1 and GIP concentrations. Via this mechanism, insulin secretion is glucose-dependently stimulated and glucagon secretion inhibited. This results in a low risk for hypoglycemia. Furthermore, DPP-4 inhibitors are weight-neutral. Linagliptin is a novel DPP-4 inhibitor that, in contrast to the other members of this drug class, is eliminated by a biliary/hepatic route rather than by renal elimination. This property allows the use of linagliptin in type 2 diabetic patients with normal kidney function as well as in patients with renal insufficiency without dose adjustments. In comparative clinical studies, linagliptin was noninferior to other established antidiabetic agents, especially to metformin and sulfonylurea. It showed a superior safety profile over glimepiride regarding hypoglycemia, weight gain, a composite cardiovascular endpoint, and stroke. This review gives an overview on the efficacy and safety of linagliptin in comparison to the classical oral antidiabetic drugs as well as to the other DPP-4 inhibitors. |
Mendeley readers
The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 1% |
| Netherlands | 1 | 1% |
| Unknown | 72 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 13 | 18% |
| Student > Bachelor | 13 | 18% |
| Student > Ph. D. Student | 10 | 14% |
| Researcher | 8 | 11% |
| Student > Postgraduate | 4 | 5% |
| Other | 11 | 15% |
| Unknown | 15 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 38% |
| Agricultural and Biological Sciences | 10 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 9% |
| Biochemistry, Genetics and Molecular Biology | 5 | 7% |
| Social Sciences | 2 | 3% |
| Other | 4 | 5% |
| Unknown | 18 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 January 2013.
All research outputs
#22,830,981
of 25,457,297 outputs
Outputs from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#1,003
of 1,184 outputs
Outputs of similar age
#258,817
of 289,379 outputs
Outputs of similar age from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#9
of 11 outputs
Altmetric has tracked 25,457,297 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,184 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 289,379 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.